Healthcare AI Under the EU AI Act's High-Risk Classification
The EU AI Act classifies healthcare AI as high-risk under Annex III, Area 5 (Access to essential private and public services). AI systems used as safety components of medical devices, or AI systems that are medical devices themselves, fall under Annex I, Section A. This dual classification means virtually every healthcare AI application, from clinical decision support to diagnostic assistance to patient triage, must comply with the Act's most demanding requirements.
High-risk classification under the EU AI Act triggers mandatory obligations across six domains: risk management systems (Article 9), data governance (Article 10), technical documentation (Article 11), record-keeping (Article 12), transparency (Article 13), and human oversight (Article 14). These requirements apply to providers, deployers, importers, and distributors of healthcare AI systems.
Areebi enables healthcare organisations to meet EU AI Act high-risk requirements through built-in documentation and logging, data governance controls, and human oversight mechanisms that satisfy the Act's prescriptive obligations.
Annex III Area 5: Healthcare AI Classification
Annex III Area 5 covers AI systems intended to be used to evaluate the eligibility of natural persons for essential private and public services and benefits, including healthcare services. This encompasses AI systems that assess patient eligibility for treatments, triage patients, prioritise healthcare resource allocation, or evaluate health insurance coverage.
Separately, AI systems that qualify as medical devices under Regulation (EU) 2017/745 (MDR) are classified as high-risk under Annex I, Section A. This includes AI-based diagnostic tools, clinical decision support systems with a medical purpose, and AI systems that process medical data for clinical conclusions. The intersection of the AI Act and MDR creates a comprehensive regulatory framework for healthcare AI.
Conformity Assessment for Healthcare AI
High-risk healthcare AI systems must undergo conformity assessment (Article 43) before being placed on the EU market. For AI systems covered under Annex I (medical devices), the conformity assessment follows the procedure established by the relevant medical device regulation, which typically involves a notified body. For Annex III systems, providers may conduct internal conformity assessments with quality management systems per Article 17.
Areebi supports conformity assessment by providing the technical documentation, risk management records, testing evidence, and ongoing monitoring data that assessments require. The platform's comprehensive logging generates the continuous compliance evidence needed to maintain conformity throughout the AI system's lifecycle.
How Areebi Supports EU AI Act Compliance for Healthcare AI
Areebi addresses the EU AI Act's healthcare requirements through controls mapped to each high-risk obligation. Risk management (Article 9) is supported through continuous monitoring of AI interactions, anomaly detection, and risk assessment documentation that demonstrates ongoing compliance. Data governance (Article 10) is enforced through the DLP engine and workspace data controls that ensure training and operational data meets the Act's quality requirements.
Technical documentation (Article 11) is generated from platform metadata including system configurations, processing logic documentation, data flow maps, and performance monitoring records. Record-keeping (Article 12) is satisfied through immutable audit logs that capture every AI interaction with full provenance. Transparency (Article 13) is addressed through user-facing documentation of AI capabilities and limitations.
Human oversight (Article 14) is built into Areebi's architecture. Healthcare AI outputs are logged and can be configured to require human review before clinical action. Override mechanisms allow clinicians to intervene in AI-assisted processes, and all interventions are documented in the audit trail.